Ligand Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Ligand Pharmaceuticals Inc LGND.OQ reported quarterly adjusted earnings of $1.33​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $1.20. The mean expectation of seven analysts for the quarter was for earnings of $1.20 per share. Wall Street expected results to range from $1.06 to $1.36 per share.

• Revenue rose 46.3% to $45.33 million from a year ago; analysts expected $38.70 million.

• Ligand Pharmaceuticals Inc's reported EPS for the quarter was a loss of $2.21​.

• The company reported a quarterly loss of $42.45 million.

• Ligand Pharmaceuticals Inc shares had risen by 0.5% this quarter and lost 1.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Ligand Pharmaceuticals Inc is $141.50

This summary was machine generated from LSEG data May 8 at 04:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)